https://arcturusrx.com/

About Us

Arcturus Therapeutics a global late-stage messenger RNA medicines and vaccines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://www.jnj.com/media-center/press-releases/janssen-research-development-llc-opens-janssen-labs-at-san-diego

Arcturus Therapeutics Begins Operations in Janssen Labs

March 4, 2013

https://www.healthline.com/health-news/new-covid-19-strain-arcturus-what-to-know

Funny New Covid-19 Variant has the same name as a MRNA Company Just another coincidence

>>19981266

>>19981266

https://arcturusrx.com/about-arcturus/

Has Time Line from March 4 2013 to November 14 2023

>>19981266

>>19981266

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2023-financial

New

We had considerable progress this quarter expanding our next generation STARR® vaccine platform,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “Our monovalent ARCT-154 COVID vaccine remains on track for approval in December and we reached our target enrollment for the bivalent COVID vaccine Phase 3 study, with PMDA-approval anticipated Q3 2024.”

>>19981266

>19981312

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2023-financial

We are happy to announce our expected cash runway was extended to the end of 2026,” announced Andrew Sassine, Chief Financial Officer. “A combination of lower expenses, additional development milestones and accelerated timelines for manufacturing technology transfer to CSL have contributed to the extended runway. Additionally, substantial funding was obtained by ARCALIS, our joint venture mRNA manufacturing partner, from the Japanese Government with up to $165 million committed to date. We expect this facility to become a leading manufacturer of mRNA-based vaccines and therapeutics, with the ability to manufacture vaccines within 100 days of an emerging viral strain